These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16806666)

  • 1. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
    Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
    Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
    Hammarsten J; Högstedt B
    Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B; Holthuis N; Mellström D
    Prostate Cancer Prostatic Dis; 1998 Mar; 1(3):157-162. PubMed ID: 12496910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Blood Press; 1999; 8(1):29-36. PubMed ID: 10412880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
    Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
    Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of benign prostatic hyperplasia with hyperlipemia].
    Li PJ; Zhang XH; Guo LJ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measures of obesity and metabolic syndrome in Indian Americans in northern California.
    Misra KB; Endemann SW; Ayer M
    Ethn Dis; 2006; 16(2):331-7. PubMed ID: 17682232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men.
    Han JH; Choi NY; Bang SH; Kwon OJ; Jin YW; Myung SC; Chang IH; Kim TH; Ahn SH
    Urology; 2008 Oct; 72(4):749-54; discussion 754-5. PubMed ID: 18701153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
    Hammarsten J; Högstedt B
    Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia].
    Cao B; Sun HB; Su JH; Shen MS; Cao ZG; Jia RP; Liu J
    Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(40):2823-5. PubMed ID: 21162791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
    Kwon H; Kang HC; Lee JH
    Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia.
    Nandeesha H; Koner BC; Dorairajan LN; Sen SK
    Clin Chim Acta; 2006 Aug; 370(1-2):89-93. PubMed ID: 16516184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
    Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
    Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.
    Dahle SE; Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Hsing AW
    J Urol; 2002 Aug; 168(2):599-604. PubMed ID: 12131317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between serum prostate-specific antigen level, liver function tests and lipid profile in healthy men.
    Han JH; Chang IH; Ahn SH; Kwon OJ; Bang SH; Choi NY; Park SW; Myung SC; Kim HW
    BJU Int; 2008 Nov; 102(9):1097-101. PubMed ID: 18522630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.